The new and less toxic protease inhibitor saquinavir–NO maintains anti-HIV-1 properties in vitro indistinguishable from those of the parental compound saquinavir

Boeri, 2003, Evolutionary characteristics of HIV type 1 variants resistant to protease inhibitors in the absence of drug-selective pressure, AIDS Res. Hum. Retroviruses, 19, 1151, 10.1089/088922203771881257 Boesecke, 2008, Toxicity of HIV protease inhibitors: clinical considerations, Curr. Opin. HIV AIDS, 3, 653, 10.1097/COH.0b013e328312c392 Brun-Vézinet, 1992, HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase, J. Virol. Methods, 37, 177, 10.1016/0166-0934(92)90045-F Canducci, 2010, Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir, J. Antimicrob. Chemother., 65, 425, 10.1093/jac/dkp477 Fernandez-Montero, 2009, HIV protease inhibitors: recent clinical trials and recommendations on use, Expert Opin. Pharmacother., 10, 1615, 10.1517/14656560902980202 Hruz, 2008, HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models, Curr. Opin. HIV AIDS, 3, 660, 10.1097/COH.0b013e3283139134 Johnson, 2008, Update of the drug resistance mutations in HIV-1, Top. HIV Med., 16, 138 Johnson, 2009, Update of the drug resistance mutations in HIV-1: December 2009, Top. HIV Med., 17, 138 Kempf, 1997, Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir, Antimicrob. Agents Chemother., 41, 654, 10.1128/AAC.41.3.654 Maksimovic-Ivanic, 2009, The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt, Mol. Cancer Ther., 8, 1169, 10.1158/1535-7163.MCT-08-0998 Martinez-Cajas, 2008, Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence, AIDS Rev., 10, 212 Menzo, 2003, Processivity and drug-dependence of HIV-1 protease: determinants of viral fitness in variants resistant to protease inhibitors, AIDS, 17, 663, 10.1097/00002030-200303280-00003 Paolucci, 2003, Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients, J. Antimicrob. Chemother., 51, 135, 10.1093/jac/dkg016 Ribera, 2008, Double-boosted protease inhibitor antiretroviral regimens: what role?, Drugs, 68, 2257, 10.2165/0003495-200868160-00001 Santos, 2009, Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G, J. Antimicrob. Chemother., 63, 593, 10.1093/jac/dkn526 Schütt, 2004, Long-term effects of HIV-1 protease inhibitors on insulin secretion and insulin signaling in INS-1 beta cells, J. Endocrinol., 183, 445, 10.1677/joe.1.05620 Shen, 2008, Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs, Nat. Med., 14, 762, 10.1038/nm1777 Wensing, 2010, Fifteen years of HIV protease inhibitors: raising the barrier to resistance, Antiviral Res., 85, 59, 10.1016/j.antiviral.2009.10.003